Santhera's Raxone slows loss of respiratory function in real-world DMD study

Santhera said long-term treatment with Raxone idebenone reduced the annual rate of decline in percent predicted forced vital capacity (FVC) by 50% for up to six years in the retrospective real-world SYROS study in patients with Duchenne muscular dystrophy.

Santhera Pharmaceuticals Holding AG (SIX:SANN) also said Raxone reduced the risk of bronchopulmonary adverse events and hospitalizations due to respiratory causes. SYROS enrolled 18 patients who completed the Phase III DELOS trial to receive once-daily 900 mg Raxone under expanded access programs...